Insider Buying: NextCure (NASDAQ:NXTC) Major Shareholder Purchases 3,410 Shares of Stock

NextCure, Inc. (NASDAQ:NXTC) major shareholder Adar1 Capital Management, Llc bought 3,410 shares of the company’s stock in a transaction on Wednesday, July 29th. The stock was bought at an average cost of $5.00 per share, for a total transaction of $17,050.00. Following the completion of the acquisition, the insider directly owned 393,266 shares of the company’s stock, valued at approximately $1,966,330. This represents a 0.87% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Tuesday, July 28th, Adar1 Capital Management, Llc purchased 6,400 shares of NextCure stock. The shares were bought at an average price of $4.95 per share, with a total value of $31,680.00.
• On Monday, July 27th, Adar1 Capital Management, Llc purchased 7,798 shares of NextCure stock. The stock was bought at an average cost of $5.00 per share, with a total value of $38,990.00.

NextCure Price Performance

NextCure stock traded down $0.40 during mid-day trading on Wednesday, reaching $5.02. The stock had a trading volume of 355,456 shares, compared to its average volume of 939,730. NextCure, Inc. has a one year low of $1.55 and a one year high of $15.74. The company has a 50-day moving average price of $3.76 and a two-hundred day moving average price of $8.83. The company has a market capitalization of $18.12 million, a price-to-earnings ratio of -0.29 and a beta of 1.42.

NextCure (NASDAQ:NXTC) last issued its earnings results on Thursday, May 7th. The company reported ($1.87) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.10) by $0.23. On average, equities research analysts anticipate that NextCure, Inc. will post -7.89 earnings per share for the current fiscal year.

Institutional Investors Weigh In On NextCure

Large investors have recently added to or reduced their stakes in the stock. Ikarian Capital LLC bought a new stake in NextCure in the 4th quarter worth approximately $3,382,000. Squadron Capital Management LLC bought a new position in shares of NextCure during the 4th quarter valued at $3,363,000. Exome Asset Management LLC purchased a new position in shares of NextCure in the 4th quarter worth $2,341,000. AWM Investment Company Inc. purchased a new position in shares of NextCure in the 4th quarter worth $1,665,000. Finally, Cable Car Capital LP grew its holdings in shares of NextCure by 13.1% in the second quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock worth $349,000 after acquiring an additional 88,040 shares during the period. Institutional investors own 42.65% of the company’s stock.

Analyst Upgrades and Downgrades

NXTC has been the subject of a number of research analyst reports. Zacks Research raised NextCure from a “strong sell” rating to a “hold” rating in a report on Thursday, June 11th. Weiss Ratings cut NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 7th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of NextCure in a report on Wednesday, July 15th. Finally, Wall Street Zen lowered NextCure from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $19.00.

About NextCure

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.